Shantel
Key Takeaways:
- Dragonfly Biosciences UK expands its retail footprint into Superdrug, part of the world’s largest international health and wellness retailer – the A.S. Watson Group.
- Six popular Dragonfly CBD oral drop products will be made available in Superdrug.
- Dragonfly CBD is already a market leader in the UK, with significant presence in European and Australian markets.
- According to Fortune Business Insights, the global CBD market is predicted to surge from USD $3.6 billion to USD $55 Billion by 2028.
Broadening Horizons: Dragonfly Biosciences UK
Dragonfly Biosciences UK, recognized as Europe’s largest and leading seed-to-shelf range of CBD products, has announced its expansion into Superdrug. This move signals a significant escalation of the brand’s already impressive high-street presence, bolstering accessibility for customers across the UK and the Republic of Ireland. The rollout includes six of Dragonfly’s acclaimed CBD oral drop products.
Dragonfly Biosciences UK was established with an unwavering commitment to innovation and quality. The company’s dedication to these principles has catalyzed its success, propelling it to the forefront of the thriving CBD industry. Today, Dragonfly CBD products dominate the UK market and are widely available across Europe and Australia.
Fanning the Flames of Success: Dragonfly CBD
“Superdrug has established itself as a leading, innovative multichannel health and beauty destination in the UK. We are committing to significant investments in initiatives to provide broader access to customers,” stated Regan Saveall, CEO of Dragonfly Biosciences UK.
Dragonfly is not a newcomer to breaking barriers; it was the first CBD brand stocked by Boots UK. The brand’s strategic expansion into Superdrug positions it further in line with the skyrocketing trajectory of the global CBD market. As per Fortune Business Insights, this market is projected to escalate from USD $3.6 billion to an astonishing USD $55 billion by 2028.
Dragonfly CBD: Beyond UK Borders
While the Superdrug expansion primarily impacts the UK, Saveall emphasized its global significance, remarking, “A.S. Watson is part of the Hong Kong conglomerate CK Hutchison Holdings, making this an exciting development as we expand globally, particularly in the Asia-Pacific region.”
In addition to its ongoing international expansion, Dragonfly Biosciences UK is also set to be listed on the ASX from August 2023 under the symbol DRF, adding another feather to its cap.
About Dragonfly Biosciences UK
Founded in the UK, Dragonfly Biosciences has cultivated an international reputation for its award-winning CBD oils and skincare products. The company adheres to a ‘seed to shelf’ quality assurance, underpinning its dedication to extensive research, development, and rigorous quality controls. All Dragonfly CBD products are made from certified organic hemp grown on the company’s own land, with extraction taking place in licensed, dedicated facilities.
Dragonfly Biosciences UK is not just about ensuring high-quality, consistent products; it’s also about looking after the planet. The company employs environmentally sustainable practices that significantly reduce its environmental footprint. A prime example of this is its use of hemp cultivation, a process that actually sequesters more CO2 than it produces.
The company’s commitment to innovation and quality is reflected in its product line. Dragonfly CBD oral drops are available in a range of strengths and flavors, with some preparations including Vitamin D to facilitate consumers obtaining the UK government’s recommended daily dose of this essential vitamin.
The future looks bright for Dragonfly Biosciences UK. As Saveall concluded, “Moving through the latter part of 2023 and beyond, we will continue to introduce global market firsts and our business expansion strategies will propel us into new markets as we strive to create the next generation of health and wellness innovation.”
